To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: BREAST CANCER: Arimidex More Effective Than Nolvadex For Advanced Breast Cancer URL: http://www.pslgroup.com/dg/14FB16.htm Doctor's Guide December 10, 1999
SAN ANTONIO, TX -- December 10, 1999 -- The 22nd Annual San Antonio Breast Cancer Symposium, one of the world's leading meetings devoted to new advances in breast cancer, featured several presentations on new data involving AstraZeneca's breast cancer drugs. The results from the North American and the TARGET - Tamoxifen® (tamoxifen citrate) or Arimidex® (anastrozole) Randomized Group Efficacy and Tolerability - European Study showed that women in the study treated with Nolvadex (tamoxifen) had a 13 percent higher risk of their disease progressing than those treated with Arimidex.(1) This suggests Arimidex could be a more effective treatment option for many postmenopausal women with advanced breast cancer. The combined studies were randomized, double-blind studies of more than 1000 subjects designed to demonstrate the efficacy of Arimidex and Nolvadex treatments in postmenopausal women with advanced breast cancer. A total of 1021 patients were included in the studies. Professor Aman Buzdar, from the University of Texas M.D. Anderson Cancer Center said, "We know that Tamoxifen and Arimidex are both effective treatments for women with advanced breast cancer but, until now, the two have never been compared directly in a clinical trial. This is the first time that we have seen an aromatase inhibitor prove to be as effective as Tamoxifen." Arimidex is a selective, non-steroidal aromatase inhibitor and differs from Tamoxifen because it inhibits a key step in the production of estrogen. Arimidex is currently available in most countries, including the U.S., for the treatment of advanced breast cancer in postmenopausal women following progression on tamoxifen or other antiestrogens. The ATAC trial (Arimidex, Tamoxifen Alone or in Combination) for adjuvant use of Arimidex is ongoing.(2) References: 1. Nabholtz, JM et. al., "The North American and TARGET (Tamoxifen or ARIMIDEX Randomized Group Efficacy and Tolerability) Study," Cross Cancer Institute, Canada. Presented at the 22nd Annual San Antonio Breast Cancer Symposium 1999. 2. Arimidex PIB. Related Links: Tamoxifen (tamoxifen citrate), Arimidex (anastrozole), Astra and Zeneca. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.